Propanc Biopharma, Inc. (PPCB)
NASDAQ: PPCB · Real-Time Price · USD
0.168
-0.004 (-2.04%)
At close: Mar 5, 2026, 4:00 PM EST
0.168
-0.000 (-0.12%)
After-hours: Mar 5, 2026, 7:23 PM EST
Propanc Biopharma Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
| TTM
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| Selling, General & Admin | 64.91 | 57.05 | 1.29 | 1.53 | 1.73 | 1.58 | |
| Research & Development | 0.19 | 0.22 | 0.25 | 0.25 | 0.26 | 0.23 | |
| Operating Expenses | 65.1 | 57.28 | 1.54 | 1.78 | 1.99 | 1.81 | |
| Operating Income | -65.1 | -57.28 | -1.54 | -1.78 | -1.99 | -1.81 | |
| Interest Expense | -0.72 | -0.56 | -0.67 | -0.53 | -0.57 | -0.45 | |
| Interest & Investment Income | 0 | 0 | 0 | 0 | 0.01 | 0 | |
| Currency Exchange Gain (Loss) | -0.07 | -0.09 | 0.02 | 0.01 | -0.04 | 0.03 | |
| Other Non Operating Income (Expenses) | 0.46 | -0.12 | 0.18 | -0.53 | -0.1 | -0.01 | |
| EBT Excluding Unusual Items | -65.44 | -58.05 | -2 | -2.83 | -2.7 | -2.24 | |
| Other Unusual Items | -0.63 | -0.87 | 0.05 | 0.04 | -0.02 | 0.1 | |
| Pretax Income | -66.07 | -58.92 | -1.95 | -2.79 | -2.71 | -2.14 | |
| Income Tax Expense | - | - | -0.13 | -0.13 | -0.05 | -0.11 | |
| Net Income | -66.07 | -58.92 | -1.82 | -2.66 | -2.66 | -2.03 | |
| Preferred Dividends & Other Adjustments | 0.93 | - | 0.19 | 0.47 | 0.7 | 0.39 | |
| Net Income to Common | -67 | -58.92 | -2.01 | -3.13 | -3.36 | -2.42 | |
| Shares Outstanding (Basic) | 10 | 4 | - | - | - | - | |
| Shares Outstanding (Diluted) | 10 | 4 | - | - | - | - | |
| EPS (Basic) | -6.45 | -14.85 | - | - | - | - | |
| EPS (Diluted) | -6.45 | -14.85 | - | - | - | - | |
| Free Cash Flow | -3.13 | -0.41 | -0.94 | -1.11 | -1.44 | -1.15 | |
| Free Cash Flow Per Share | -0.30 | -0.10 | - | - | - | - | |
| EBITDA | -65.1 | -57.28 | -1.54 | -1.77 | -1.99 | -1.81 | |
| D&A For EBITDA | 0 | 0 | 0 | 0 | 0 | 0 | |
| EBIT | -65.1 | -57.28 | -1.54 | -1.78 | -1.99 | -1.81 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.